Total views : 88

Blood Kinetics and Biodistribution = Study of Dialdehyde Cellulose-Desferrioxamine Microcarrierby Gamma Scintigraphy

Affiliations

  • Department of Basic and Applied Sciences, School of Engineering, GD Goenka University, Gurgaon − 122103, Haryana, India
  • Institute of Nuclear Medicine and Allied Sciences (INMAS), DRDO, Timarpur – 110054, New Delhi, India
  • Centre for Biomedical Engineering, Indian Institute of Technology, Hauz Khas − 110016, New Delhi,, India

Abstract


Objectives: To observe the bio-distribution and change in blood kinetics of iron chelating drug-desferrioxamine covalently bound to high-molecular weight dialdehyde cellulose. Methods/Statistical Analysis: The DAC-DFO conjugate and free desferrioxamine were labeled with radiotracer 99mTc. In vitro studies, to establish quality control parameters, were performed by instant thin layer chromatography followed by intravenous administration of radio complexes to the rabbits. Gamma camera imaging was carried out and bio-distribution parameters of both conjugate and free drug were evaluated and compared. Findings: Both polymers based and free desferrioxamine samples exhibited > 90% radiolabelling efficiency and a high in-vitro stability. There was significant improvement in blood circulation time after covalent binding of DFO to DAC (at 1500 min) compared to free DFO (at 900 min) After a single injection of 99mTc-DAC-DFO, the highest distribution was observed in the liver at 19.5 minutes with lower uptake in kidneys and urinary bladder till 30min. On the other hand, the highest distribution of free DFO in liver was highest at only 1 minute post-administration. Application/Improvements: The bioavailability of desferrioxamine was found to be enhanced upto several folds after conjugation to oxidized cellulose.

Keywords

99mtc Labeling, Biodistribution, Desferrioxamine, Dialdehyde Cellulose, Scintigraphy

Full Text:

 |  (PDF views: 61)

References


  • Hesseltine CW, Pidacks C, Whitehill AR, Bohonos N, Hutchings BL, Williams JH. Coprogen A New Growth Factor for coprophilicfungi, Journal of the American Chemical Society. 1952; 74(5):1362. Crossref
  • Fielding J. Storage Iron and desferrioxamine, Proceedings of the Royal Society of Medicine. 1970; 63(12):1218–21.PMid:5490766 PMCid:PMC1812354.
  • Markum AH, Iskanda W, Keng KL, Odang O. Iron Excretion in thalassemia after the Administration of Chelating Agents, PaediatrIndones.1968; 9(3):89−98.
  • Seshadri R, Colebatch JH, Fisher R. Urinary Ironex Cretion in Thalassemia afterd Desferrioxamine Administration, Archives Disease in Childhood, Archives Disease inChildhood. 1974; 49(3):195−99. https://doi.org/10.1136/ adc.49.3.195. PMid:4825624 PMCid:PMC1648673.
  • Diwany M, Gabr M, El Hefni A, Mokhtar N.Desferrioxamine in Thalassemia, Archives Disease in Childhood. 1968; 43(229):340−43. Crossref. PMid:5652711 PMCid:PMC2019950.
  • Tufano TP, Pecoraro VL, Raymond KN. Ferric Ion Sequestering Agents Kinetics of Iron Release from Ferritin to Catechoylamides, Biochimica et Biophysica Acta. 1981; 668(3):420−28. Crossref.
  • Kontoghiorghes GJ, Evans RW. Site Specificity of Iron Removal from Transferrin by a-Keto Hydroxypyridine Chelators, FEBS Letters. 1985; 189(1):141–44. Crossref.
  • Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C. Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron-Loaded Subjects, British Journal Haematology. 1979; 42(4):547−55. Crossref.PMid:476006
  • 9. Anita A, Siobhan W, Kevin GE. Desferrioxamine Related Maculopathy A Case Report, Am. J. Hematol. 2004; 76(4):386–88. Crossref. PMid:15282675.
  • 10. Cases A, Kelly J, Sabater F, Torras A, Gri-o MC, Lopez-Pedret J, Revert L. Ocular and Auditory Toxicity in Hemodialyzed Patients Receiving Desferrioxamine, Nephron. 1990; 56(1):19−23. Crossref. PMid:2234245.
  • Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IY. Pulmonary Toxic Effects of Continuous Desferrioxamine Administration in Acute Iron Poisoning, Lancet. 1992; 339(8795):699−701. Crossref.
  • Caballero LG. Auditory Visual and Neurologic Toxicity of Deferoxamine, Revista Medica de Chile. 1989; 117(5):557−61. PMid:2519168.
  • Porter JB, Huehns ER. The Toxic Effects of Desferrioxamine, Baillieres Clin Haematol. 1989; 2(2):459−74. Crossref.
  • Hallaway PE, Eaton JW, Panter SS, Hedlund BE. Modulation of Deferoxamine Toxicity and Clearance by Covalent Attachment to Biocompatible Polymers, Proceedings Natl. Acad. Science. 1989; 86(24):10108−12. Crossref.
  • Tyagi P, Kumar A, Gupta D, Singh H. Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier, AAPS, Pharma Science Technology. 2017; 18(1):156−65. Crossref. PMid:26912356.
  • Kim UJ, Wada M, Kuga S. Solubilization of Dialdehyde Cellulose by Hot Water, Carbohydrate Polymers. 2004; 56(1):7–10. Crossref.
  • Whitten CF, Gibson GW, Good MH, Goodwin FJ, Brough AJ. Studies in Acute Iron Poisoning. I.
  • Desferrioxaminein the Treatment of Acute Iron Poisoning Clinical Observations Experimental Studies and Theoretical Considerations, Pediatrics. 1965; 36(3):322−35.PMid:5829325.
  • Gillette JR. Overview of Drug–Protein Binding, Ann. N.Y. Acadamic Science. 1973; 226:6–17. Crossref.
  • PMid:4588445.

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.